8Frolov A,Chahwan S,Ochs M,et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther,2003,2:699-709.
9Croom KF,Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs,2003,63:513-522.
10Schindler T,Bornmann W,Pellicena P,et al. Structural mechanism for STI571 inhibition of abelson tyrosine kinase. Science,2000,289:1938-1942.
6BENJAMIN RS,RANKIN C,FLETCHER C,et al.Phase Ⅲ dose-randomized study of imatinib mesylate (ST1571)for GIST:Intergroup S0033 early results[J].Proc Am Soc Clin Oncol,2003,22:A3271.
7JOENSUU H,ROBERTS P,SARLOMO-RIKALA M,et al.Effect of the tyrosine kinase inhibitor ST1571 in patient with metastatic gastrointestinal stromal tumor[J].N Eugl J Med,2001,344 (14):1052-1056.
8VAN OOSTEROM AT,JUDON IR,VERWEIJ J,et al.Update of phase Ⅰ study of imatinib(ST1571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors:a report of the EORTC soft tissue and bone sarcoma group[J].Eur J Cancer,2002,38(Suppl 5):S83-S87.
9DEMTRI GD,VON MEHREN M,BLANKE CD,et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J].N Engl J Med,2002,347 (7):472-480.
10DRUKER BJ,TALPAZ M,RESTA DJ,et al.Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia[J].N Engl J Med,2001,344 (14):1031 -1037.
